Otimiza??o do prot?tipo LDQMC-014: uma acridinona inibidora da polimeriza??o de Tubulina

Detalhes bibliográficos
Autor(a) principal: Fonseca, Marina Brand?o da
Data de Publicação: 2020
Tipo de documento: Dissertação
Idioma: por
Título da fonte: Biblioteca Digital de Teses e Dissertações da UFRRJ
Texto Completo: https://tede.ufrrj.br/jspui/handle/jspui/6290
Resumo: Today, cancer is one of the most deadly diseases in the world. Breast cancer is the fifth most lethal, and its triple negative subtype has the highest mortality rate. There is no specific treatment for the triple negative subtype, and the high rates of disease recurrence and metastasis make it necessary to search for new forms of treatment. A multicomponent reaction is a type of reaction for chemical synthesis, where three or more reagents react to form a single product with a high degree of chemical diversity, and the Hantzsch reaction is one of the first reactions of this type reported. In the present work, a series of molecules were synthesized, using as a basis the Hantzsch reaction and structures analogous to natural products such as Colchicine and Podophyllotoxin, aiming at the optimization of the LDQMC-014 (7-(3,4,5-trimethoxyphenyl)-9,10,11,12-tetrahydrobenzo[c]acridin-8(7H)-one) prototype, whose results in previous works demonstrate good cytotoxic activity in vitro, with a profile of inhibition of Tubulin polymerization (target widely validated as anticancer). Varied yields were obtained with confirmation of the structures by carbon and hydrogen NMR. Once the LDQMC-014 compound obtained satisfactory results, it was sought to optimize the synthesis results. Systematic changes were made in the synthesis parameters, which promoted an increase of more than 78 % in the reaction yield. The enantiomers of LDQMC-014 were separated by chiral chromatography, which provided good enantiomeric separation, which subsequently allowed the determination of the absolute configuration of the asymmetric center present by circular dichroism. Once the enantiomers were isolated, their biological evaluations were performed in order to determine their activity, as well as a molecular modeling study to predict the interaction of the isolated enantiomers with the Tubulin protein. That enantiomers interact differently with the protein in both the in silico and the in vitro tests. The molecular modeling study was extended to all intended acridinones to predict a possible interaction with the Tubulin protein. A cell migration test (Wound Healing) was performed for some of the obtained acridinones, which determined the inhibition profile of cell migration, a desired characteristic in metastasis cases.
id UFRRJ-1_418642f89993f0b0f2bd9b70e905be00
oai_identifier_str oai:localhost:jspui/6290
network_acronym_str UFRRJ-1
network_name_str Biblioteca Digital de Teses e Dissertações da UFRRJ
repository_id_str
spelling Graebin, Cedric Stephan966.049.800-49http://lattes.cnpq.br/4900857097448760Andricopulo, Adriano Defini615.855.560-68Graebin, Cedric StephanK?mmerle, Arthur EngenLimberger, Jones137.792.107-70http://lattes.cnpq.br/8701042043901034Fonseca, Marina Brand?o da2023-01-30T18:02:50Z2020-01-28FONSECA, Marina Brand?o da. Otimiza??o do prot?tipo LDQMC-014: uma acridinona inibidora da polimeriza??o de Tubulina. 2020. 129 f. Disserta??o (Mestrado em Qu?mica) - Instituto de Qu?mica, Universidade Federal Rural do Rio de Janeiro, Serop?dica, RJ, 2020.https://tede.ufrrj.br/jspui/handle/jspui/6290Today, cancer is one of the most deadly diseases in the world. Breast cancer is the fifth most lethal, and its triple negative subtype has the highest mortality rate. There is no specific treatment for the triple negative subtype, and the high rates of disease recurrence and metastasis make it necessary to search for new forms of treatment. A multicomponent reaction is a type of reaction for chemical synthesis, where three or more reagents react to form a single product with a high degree of chemical diversity, and the Hantzsch reaction is one of the first reactions of this type reported. In the present work, a series of molecules were synthesized, using as a basis the Hantzsch reaction and structures analogous to natural products such as Colchicine and Podophyllotoxin, aiming at the optimization of the LDQMC-014 (7-(3,4,5-trimethoxyphenyl)-9,10,11,12-tetrahydrobenzo[c]acridin-8(7H)-one) prototype, whose results in previous works demonstrate good cytotoxic activity in vitro, with a profile of inhibition of Tubulin polymerization (target widely validated as anticancer). Varied yields were obtained with confirmation of the structures by carbon and hydrogen NMR. Once the LDQMC-014 compound obtained satisfactory results, it was sought to optimize the synthesis results. Systematic changes were made in the synthesis parameters, which promoted an increase of more than 78 % in the reaction yield. The enantiomers of LDQMC-014 were separated by chiral chromatography, which provided good enantiomeric separation, which subsequently allowed the determination of the absolute configuration of the asymmetric center present by circular dichroism. Once the enantiomers were isolated, their biological evaluations were performed in order to determine their activity, as well as a molecular modeling study to predict the interaction of the isolated enantiomers with the Tubulin protein. That enantiomers interact differently with the protein in both the in silico and the in vitro tests. The molecular modeling study was extended to all intended acridinones to predict a possible interaction with the Tubulin protein. A cell migration test (Wound Healing) was performed for some of the obtained acridinones, which determined the inhibition profile of cell migration, a desired characteristic in metastasis cases.quinto mais letal, sendo seu subtipo triplo negativo o que apresenta maior taxa de mortalidade. N?o existe tratamento espec?fico para o subtipo triplo negativo, e com as elevadas taxas de rein-cid?ncia da doen?a e de met?stase faz com que seja necess?ria a busca por novas formas de trata-mento. A rea??o multicomponente ? um tipo de rea??o utilizada na s?ntese de produtos qu?micos, onde tr?s ou mais reagentes levam a forma??o de um ?nico produto, com alto grau de diversidade qu?mica, sendo a rea??o de Hantzsch uma das primeiras rea??es desse tipo relatada. No presente trabalho foram sintetizadas diversas mol?culas, utilizando como base a rea??o de Hantzsch e estruturas an?logas ? produtos naturais como a Colchicina e Podofilotoxina, visando a otimiza??o do prot?tipo LDQMC-014 (7-(3,4,5-trimetoxifenil)-9,10,11,12-tetraidrobenzo[c]acridin-8(7H)-ona), cujos resultados em trabalhos anteriores demonstram uma boa atividade citot?xica in vitro, tendo um perfil de inibi??o da polimeriza??o de Tubulina (alvo amplamente validado como antic?ncer). Obtiveram-se rendimentos variados, com confirma??o das estruturas realizadas por RMN de carbono e hidrog?nio. Uma vez que o composto LDQMC-014 obteve resultados satisfa-t?rios, buscou-se otimizar os resultados de sua s?ntese. Foram realizadas mudan?as sistem?ticas nos par?metros da s?ntese, que promoveu um aumento de mais de 78% no rendimento. Realizou-se a separa??o dos enanti?meros do composto LDQMC-014, atrav?s de cromatografia quiral, que proporcionou uma boa separa??o enantiom?ricas, que, posteriormente permitiu a determina??o da configura??o absoluta do centro assim?trico presente atrav?s do dicro?smo circular. Uma vez que os enanti?meros estavam isolados, foram realizadas suas avalia??es biol?gicas in vitro (ensaio de citotoxicidade, migra??o celular, polimeriza??o de Tubulina e an?lise do ciclo celular), a fim de determinar a atividade de cada um, al?m de um estudo de modelagem molecular para prever a intera??o dos enanti?meros isolados com a prote?na Tubulina, chegando-se a conclus?o que os enanti?meros interagem de maneira distintas com a prote?na tanto nos testes in silico quanto nos teste in vitro. O estudo de modelagem molecular foi ampliado para todas acridinonas pretendidas a fim de prever uma poss?vel intera??o com a prote?na Tubulina. Realizou-se teste de migra??o celular (Wound Healing), para algumas das acridinonas obtidas, que determinou o perfil de inibi??o da migra??o celular, caracter?stica desejada em casos de met?stase.Submitted by Jorge Silva (jorgelmsilva@ufrrj.br) on 2023-01-30T18:02:50Z No. of bitstreams: 1 2020 - Marina Brand?o da Fonseca.pdf: 2927723 bytes, checksum: f402c8b500ccf14a6fee41d64330174a (MD5)Made available in DSpace on 2023-01-30T18:02:50Z (GMT). No. of bitstreams: 1 2020 - Marina Brand?o da Fonseca.pdf: 2927723 bytes, checksum: f402c8b500ccf14a6fee41d64330174a (MD5) Previous issue date: 2020-01-28CAPES - Coordena??o de Aperfei?oamento de Pessoal de N?vel SuperiorFAPERJ - Funda??o Carlos Chagas Filho de Amparo ? Pesquisa do Estado do Rio de Janeiroapplication/pdfhttps://tede.ufrrj.br/retrieve/72013/2020%20-%20Marina%20Brand%c3%a3o%20da%20Fonseca.pdf.jpgporUniversidade Federal Rural do Rio de JaneiroPrograma de P?s-Gradua??o em Qu?micaUFRRJBrasilInstituto de Qu?micaALBINI, A. et al. A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer research, v. 47, n. 12, p. 3239?45, jun 1987. ISSN 0008-5472. Citado na p?gina 73. ANVISA. Tecentriq?R (atezolizumabe): nova indica??o - Informa??es T?cnicas - Anvisa. 2019. Dispon?vel em: <http://portal.anvisa.gov.br/informacoes-tecnicas13?p{\_}p{\_}id=101{\_ }INSTANCE{\_}WvKKx2fhdjM2{&}p{\_}p{\_}col{\_}id=column-2{&}p{\_}p{\_}col{\_ }pos=1{&}p{\_}p{\_}col{\_}count=2{&}{\_}101{\_}INSTANCE{\_}WvKKx2fhdjM2{\_ }groupId=219201{&}{\_}101{\_}IN>. Citado na p?gina 3. ARNST, K. E. et al. Current advances of tubulin inhibitors as dual acting small molecules for cancer therapy. Medicinal Research Reviews, v. 39, n. 4, p. 1398?1426, 2019. ISSN 10981128. Citado na p?gina 5. BARREIRO, E. J. et al. Modelagem molecular: uma ferramenta para o planejamento racional de f?rmacos em qu?mica medicinal. [S.l.], 1997. v. 20, n. 1. Citado na p?gina 13. BARREIRO, E. J.; FRAGA, C. A. M. Qu?mica medicinal: as bases moleculares da a??o dos f?rmacos. 3a. ed. [S.l.]: Artmed, 2015. 608 p. ISBN 978-8582711170. Citado na p?gina 12. BIGGS-HOUCK, J. E.; YOUNAI, A.; SHAW, J. T. Recent advances in multicomponent reactions for diversity-oriented synthesis. Current Opinion in Chemical Biology, Elsevier Ltd, v. 14, n. 3, p. 371?382, 2010. ISSN 13675931. Citado na p?gina 7. CHUNG, T. W. et al. Multicomponent Synthesis of Functionalized Tetrahydroacridinones: Insights into a Mechanistic Route. Organic Letters, v. 17, n. 21, p. 5368?5371, 2015. ISSN 15237052. Citado 3 vezes nas p?ginas 8, 10 e 11. CLINICALTRIALS. Search of: AVE8062 - List Results - ClinicalTrials.gov. 2019. Dispon?vel em: <https://clinicaltrials.gov/ct2/results?cond={&}term=AVE8062{&}cntry={&}state={&}>. Citado na p?gina 6. CLINICALTRIALS. Search of: BNC-105p - List Results - ClinicalTrials.gov. 2019. Dispon?vel em: <https://clinicaltrials.gov/ct2/results?term=BNC-105p{&}age{\_}v={&}gndr={&}type= {&}rsl>. Citado na p?gina 6. CLINICALTRIALS. Search of: CA-1P - List Results - ClinicalTrials.gov. 2019. Dispon?vel em: <https://clinicaltrials.gov/ct2/results?cond={&}term=CA-1P{&}cntry={&}state={&}>. Citado na p?gina 6. CLINICALTRIALS. Search of: CA-4P - List Results - ClinicalTrials.gov. 2019. Dispon?vel em: <https://clinicaltrials.gov/ct2/results?cond={&}term=CA-4P{&}cntry={&}state={&}>. Citado na p?gina 6. CLINICALTRIALS. Search of: CKD-516 - List Results - ClinicalTrials.gov. 2019. Dispon?vel em: <https://clinicaltrials.gov/ct2/results?term=CKD-516{&}age{\_}v={&}gndr={&}type={&}rsl>. Citado na p?gina 6. CLINICALTRIALS. Search of: ZD6126 - List Results - ClinicalTrials.gov. 2019. Dispon?vel em: <https://clinicaltrials.gov/ct2/results?cond={&}term=ZD6126{&}cntry={&}state={&}>. Citado na p?gina 6. CRABB?, P. Actividad optica, dispersi?n rotatoria optica y dicroismo circular en qu?mica organica. [S.l.]: Programa Regional de Desarrollo Cient?fico y Tecnol?gico, 1974. 68 p. ISBN 082701418X 9780827014183. Citado na p?gina 45. DAWOOD, S. Triple-Negative Breast Cancer. Drugs, v. 70, n. 17, p. 2247?2258, dec 2010. ISSN 0012-6667. Citado na p?gina 2. DEANGELIS, G.; WILDMAN, W. Circular dichroism studies?I: A quadrant rule for the optically active aromatic chromophore in rigid polycyclic systems. Tetrahedron, v. 25, n. 20, p. 5099?5112, jan 1969. ISSN 00404020. Citado na p?gina 45. DUMONTET, C.; JORDAN, M. A. Microtubule-binding agents: a dynamic field of cancer therapeutics. Nature Reviews Drug Discovery, v. 9, n. 10, p. 790?803, oct 2010. ISSN 1474-1776. Citado na p?gina 5. EVDOKIMOV, N. M. et al. Structural Simplification of Bioactive Natural Products with Multicomponent Synthesis. 3. Fused Uracil-Containing Heterocycles as Novel Topoisomerase- Targeting Agents. Journal of Medicinal Chemistry, v. 54, n. 7, p. 2012?2021, apr 2011. ISSN 0022-2623. Citado na p?gina 51. FONSECA, M. B. S?ntese de heterociclos com atividade antic?ncer. 2017. Trabalho de conclus?o de curso (Gradua??o). UFRRJ, Serop?dica. Citado 6 vezes nas p?ginas 13, 14, 17, 30, 38 e 69. FOULKES, W. D.; SMITH, I. E.; REIS-FILHO, J. S. Triple-Negative Breast Cancer. New England Journal of Medicine, v. 363, n. 20, p. 1938?1948, nov 2010. ISSN 0028-4793. Citado 2 vezes nas p?ginas 2 e 3. GRAEBIN, C. S. et al. Multicomponent Reactions for the Synthesis of Bioactive Compounds: A Review. Current Organic Synthesis, v. 16, n. 6, p. 855?899, nov 2019. ISSN 15701794. Citado na p?gina 7. BROOKS, W. H.; GUIDA, W. C.; DANIEL, K. G. The Significance of Chirality in Drug Design and Development. Current Topics in Medicinal Chemistry, v. 11, n. 7, p. 760?770, apr 2011. ISSN 15680266. Citado na p?gina 12. HANTZSCH, A. Ueber die Synthese pyridinartiger Verbindungen aus Acetessig?ther und Aldehydammoniak. Justus Liebig?s Annalen der Chemie, v. 215, n. 1, p. 1?82, 1882. ISSN 00754617. Citado na p?gina 8. HSL. C?ncer de mama triplo-negativo - Hospital S?rio-Liban?s. 2019. Dispon?vel em: <https://www.hospitalsiriolibanes.org.br/sua-saude/Paginas/ cancer-mama-triplo-negativo-imunoterapia-tratamento.aspx>. Citado na p?gina 2. HYEDA, A.; SBARDELLOTTO, ?.; DA COSTA, M. Uma an?lise preliminar dos custos em quimioterapia ambulatorial no sistema de sa?de suplementar A preliminary analysis of the costs for outpatient chemotherapy in the supplementary health system. J Bras Econ Sa?de, v. 7, n. 2, p. 99?109, 2015. Citado na p?gina 1. IARC. Cancer Today. 2019. Dispon?vel em: <https://gco.iarc.fr/today/online-analysis-pie? v=2018{&}mode=cancer{&}mode{_}population=continents{&}population= 900{&}populations={&}key=total{&}sex=0{&}cancer=39{&}type=0{&}statistic= 5{&}prevalence=0{&}population{_}group=0{&}ages{_}group{%}>. Citado na p?gina 2. IARC. Cancer Today. 2019. Dispon?vel em: <https://gco.iarc.fr/today/online-analysis-pie? v=2018{&}mode=cancer{&}mode{\_}population=continents{&}population= 900{&}populations=76{&}key=total{&}sex=0{&}cancer=39{&}type=0{&}statistic= 5{&}prevalence=0{&}population{\_}group=0{&}ages{\_}group{}>. Citado na p?gina 2. IARC. Cancer Today. 2019. Dispon?vel em: <https://gco.iarc.fr/today/online-analysis-pie? v=2018{&}mode=cancer{&}mode{\_}population=continents{&}population= 900{&}populations=900{&}key=total{&}sex=0{&}cancer=39{&}type=1{&}statistic= 5{&}prevalence=0{&}population{\_}group=0{&}ages{\_}group>. Citado na p?gina 2. IARC. Cancer Today. 2019. Dispon?vel em: <https://gco.iarc.fr/today/online-analysis-pie? v=2018{&}mode=cancer{&}mode{\_}population=continents{&}population= 900{&}populations=900{&}key=total{&}sex=0{&}cancer=39{&}type=2{&}statistic= 5{&}prevalence=1{&}population{\_}group=0{&}ages{\_}group>. Citado na p?gina 2. IARC. Cancer Tomorrow. 2019. Dispon?vel em: <https://gco.iarc.fr/tomorrow/graphic-isotype? type=0{&}population=900{&}mode=population{&}sex=0{&}cancer=39{&}age{\_}group= value{&}ap>. Citado 2 vezes nas p?ginas 8 e 1. IARC. Cancer Tomorrow. 2019. Dispon?vel em: <https://gco.iarc.fr/tomorrow/graphic-isotype? type=0{&}population=900{&}mode=population{&}sex=2{&}cancer=39{&}age{\_}group= value{&}ap>. Citado 2 vezes nas p?ginas 8 e 2. INCA. Contra o triplo-negativio. Rede C?ncer 08, p. 44, 2009. Citado na p?gina 2. INCA. O que ? c?ncer? | INCA - Instituto Nacional de C?ncer. 2019. Dispon?vel em: <https://www.inca.gov.br/o-que-e-cancer>. Citado na p?gina 1. INCA. Quais os efeitos colaterais da quimioterapia? | INCA - Instituto Nacional de C?ncer. 2019. Dispon?vel em: <https://www.inca.gov.br/perguntas-frequentes/ quais-os-efeitos-colaterais-da-quimioterapia>. Citado na p?gina 1. INCA. Quimioterapia | INCA - Instituto Nacional de C?ncer. 2019. Dispon?vel em: <https://www.inca.gov.br/tratamento/quimioterapia>. Citado na p?gina 1. INCA. Tipos de c?ncer | INCA - Instituto Nacional de C?ncer. 2019. Dispon?vel em: <https://www.inca.gov.br/tipos-de-cancer/cancer-de-mama>. Citado na p?gina 2. INCA. Tratamento do c?ncer | INCA - Instituto Nacional de C?ncer. 2019. Dispon?vel em: <https://www.inca.gov.br/tratamento>. Citado na p?gina 1. KAVALLARIS, M. Microtubules and resistance to tubulin-binding agents. Nature Reviews Cancer, v. 10, n. 3, p. 194?204, mar 2010. ISSN 1474175X. Citado na p?gina 3. LI, L. et al. Recent advances in trimethoxyphenyl (TMP) based tubulin inhibitors targeting the colchicine binding site. European Journal of Medicinal Chemistry, Elsevier Masson SAS, v. 151, p. 482?494, 2018. ISSN 17683254. Citado na p?gina 5. LIANG, C. C.; PARK, A. Y.; GUAN, J. L. In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nature Protocols, v. 2, n. 2, p. 329?333, feb 2007. ISSN 1754-2189. Citado na p?gina 73. LIMA, V. L. E. Os f?rmacos e a quiralidade: uma breve abordagem. [S.l.], 1997. v. 20, n. 6. Citado na p?gina 12. MAGALHAES, L. G. Planejamento e caracteriza??o de moduladores da prote?na tubulina candidatos a f?rmacos para o tratamento de c?ncer. 2019. Tese (Doutorado). USP, S?o Carlos. Citado 8 vezes nas p?ginas 9, 3, 13, 19, 20, 55, 56 e 69. MAGALHAES, L. G. et al. Discovery of a series of acridinones as mechanism-based tubulin assembly inhibitors with anticancer activity. PLoS ONE, v. 11, n. 8, p. 1?17, 2016. ISSN 19326203. Citado 3 vezes nas p?ginas 14, 55 e 69. MAKRIYANNIS, A.; BIEGEL, D. Drug Discovery Strategies and Methods. [S.l.]: CRC Press, 2003. 338 p. ISBN 9780203913277. Citado na p?gina 3. MUSTACCHI, G.; DE LAURENTIIS, M. The role of taxanes in triple-negative breast cancer: literature review. Drug Design, Development and Therapy, p. 4303, aug 2015. ISSN 1177-8881. Citado na p?gina 2. NOBREGA, C. R.; LIMA, A. F. C. Procedures? costs related to outpatient chemotherapy treatment of women suffering from breast cancer. Revista da Escola de Enfermagem da USP, v. 48, n. 4, p. 699?705, aug 2014. ISSN 0080-6234. Citado na p?gina 1. PEREZ, E. A. Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance. Molecular Cancer Therapeutics, v. 8, n. 8, p. 2086?2095, aug 2009. ISSN 15357163. Citado na p?gina 3. PETTIT, G. R. et al. Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4. Experientia, v. 45, n. 2, p. 209?211, feb 1989. ISSN 0014-4754. Citado na p?gina 19. PROTEOMICSCREATIVE. Molecular Docking Service. 2019. Dispon?vel em: <https: //www.creative-proteomics.com/services/molecular-docking-service.htm>. Citado 2 vezes nas p?ginas 8 e 13. ROGERIO, K. R. et al. Multicomponent reactions: A brief history and their versatility for the synthesis of biologically active molecules. Revista Virtual de Quimica, v. 8, n. 6, p. 1934?1962, 2016. ISSN 19846835. Citado 2 vezes nas p?ginas 8 e 7. ROSADO, J. O. An?lise de redes de intera??es entre drogas quimioter?picas usadas no tratamento de c?ncer g?strico: explorando prote?nas e processos biol?gicos por meio de ferramentas de farmacologia de sistemas. 2010. Disserta??o (mestrado). UFRGS, Porto Alegre. Citado na p?gina 13. SAINI, A.; KUMAR, S.; SANDHU, J. S. Hantzsch reaction: Recent advances in Hantzsch 1,4-dihydropyridines. Journal of Scientific and Industrial Research, v. 67, n. 2, p. 95?111, 2008. ISSN 00224456. Citado na p?gina 9. SALUM, L. B. Planejamento de ligantes da tubulina com propriedades antitumorais. 2011. Tese (Doutorado). USP, S?o Carlos. Citado na p?gina 3. SCHMID, P. et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. New England Journal of Medicine, v. 379, n. 22, p. 2108?2121, nov 2018. ISSN 0028-4793. Citado na p?gina 3. SOLOMONS, T. W. G.; FRYHLE, C. B. Qu?mica Org?nica. 10. ed. [S.l.: s.n.], 2012. ISBN 9788521620334. Citado na p?gina 11. SOUZA, S. Estudo de inibidores de colinesterases aplicando t?cnicas de QSAR-2D (HQSAR) e docking molecular. 2012. Tese (Doutorado). UFRJ, Rio de Janeiro. Citado na p?gina 13. STEINMETZ, M. O.; PROTA, A. E. Microtubule-Targeting Agents: Strategies To Hijack the Cytoskeleton. Trends in Cell Biology, Elsevier Ltd, v. 28, n. 10, p. 776?792, 2018. ISSN 18793088. Citado 3 vezes nas p?ginas 8, 4 e 7. TRATRAT, C.; GIORGI-RENAULT, S.; HUSSON, H. A Multicomponent Reaction for the One-Pot Synthesis of 4-Aza-2,3-didehydropodophyllotoxin and Derivatives. Organic Letters, v. 4, n. 19, p. 3187?3189, sep 2002. ISSN 1523-7060. Citado 6 vezes nas p?ginas 8, 9, 10, 26, 39 e 63. WADE, R. H. On and Around Microtubules: An Overview. Molecular Biotechnology, v. 43, n. 2, p. 177?191, oct 2009. ISSN 1073-6085. Citado na p?gina 3. WERMUTH, C. G. The practice of Medicinal Chemistry. 3a. ed. [S.l.]: Academic Press, 2008. ISBN 9780123741943. Citado na p?gina 55.Rea??o multicomponentec?ncerTubulinaMulticomponent reactioncancerQu?micaOtimiza??o do prot?tipo LDQMC-014: uma acridinona inibidora da polimeriza??o de TubulinaPrototype optimization LDQMC-014: an acridinone inhibitor of Tubulin polymerizationinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/masterThesisinfo:eu-repo/semantics/openAccessreponame:Biblioteca Digital de Teses e Dissertações da UFRRJinstname:Universidade Federal Rural do Rio de Janeiro (UFRRJ)instacron:UFRRJTHUMBNAIL2020 - Marina Brand?o da Fonseca.pdf.jpg2020 - Marina Brand?o da Fonseca.pdf.jpgimage/jpeg3576http://localhost:8080/tede/bitstream/jspui/6290/4/2020+-+Marina+Brand%C3%A3o+da+Fonseca.pdf.jpgab8f7143f6da57e76b9d97505ead73f3MD54TEXT2020 - Marina Brand?o da Fonseca.pdf.txt2020 - Marina Brand?o da Fonseca.pdf.txttext/plain165805http://localhost:8080/tede/bitstream/jspui/6290/3/2020+-+Marina+Brand%C3%A3o+da+Fonseca.pdf.txt2960e5091fa598b0d3b3ff01a24bd01bMD53ORIGINAL2020 - Marina Brand?o da Fonseca.pdf2020 - Marina Brand?o da Fonseca.pdfapplication/pdf2927723http://localhost:8080/tede/bitstream/jspui/6290/2/2020+-+Marina+Brand%C3%A3o+da+Fonseca.pdff402c8b500ccf14a6fee41d64330174aMD52LICENSElicense.txtlicense.txttext/plain; charset=utf-82089http://localhost:8080/tede/bitstream/jspui/6290/1/license.txt7b5ba3d2445355f386edab96125d42b7MD51jspui/62902023-01-31 02:00:24.95oai:localhost: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Biblioteca Digital de Teses e Dissertaçõeshttps://tede.ufrrj.br/PUBhttps://tede.ufrrj.br/oai/requestbibliot@ufrrj.br||bibliot@ufrrj.bropendoar:2023-01-31T04:00:24Biblioteca Digital de Teses e Dissertações da UFRRJ - Universidade Federal Rural do Rio de Janeiro (UFRRJ)false
dc.title.por.fl_str_mv Otimiza??o do prot?tipo LDQMC-014: uma acridinona inibidora da polimeriza??o de Tubulina
dc.title.alternative.eng.fl_str_mv Prototype optimization LDQMC-014: an acridinone inhibitor of Tubulin polymerization
title Otimiza??o do prot?tipo LDQMC-014: uma acridinona inibidora da polimeriza??o de Tubulina
spellingShingle Otimiza??o do prot?tipo LDQMC-014: uma acridinona inibidora da polimeriza??o de Tubulina
Fonseca, Marina Brand?o da
Rea??o multicomponente
c?ncer
Tubulina
Multicomponent reaction
cancer
Qu?mica
title_short Otimiza??o do prot?tipo LDQMC-014: uma acridinona inibidora da polimeriza??o de Tubulina
title_full Otimiza??o do prot?tipo LDQMC-014: uma acridinona inibidora da polimeriza??o de Tubulina
title_fullStr Otimiza??o do prot?tipo LDQMC-014: uma acridinona inibidora da polimeriza??o de Tubulina
title_full_unstemmed Otimiza??o do prot?tipo LDQMC-014: uma acridinona inibidora da polimeriza??o de Tubulina
title_sort Otimiza??o do prot?tipo LDQMC-014: uma acridinona inibidora da polimeriza??o de Tubulina
author Fonseca, Marina Brand?o da
author_facet Fonseca, Marina Brand?o da
author_role author
dc.contributor.advisor1.fl_str_mv Graebin, Cedric Stephan
dc.contributor.advisor1ID.fl_str_mv 966.049.800-49
dc.contributor.advisor1Lattes.fl_str_mv http://lattes.cnpq.br/4900857097448760
dc.contributor.advisor-co1.fl_str_mv Andricopulo, Adriano Defini
dc.contributor.advisor-co1ID.fl_str_mv 615.855.560-68
dc.contributor.referee1.fl_str_mv Graebin, Cedric Stephan
dc.contributor.referee2.fl_str_mv K?mmerle, Arthur Engen
dc.contributor.referee3.fl_str_mv Limberger, Jones
dc.contributor.authorID.fl_str_mv 137.792.107-70
dc.contributor.authorLattes.fl_str_mv http://lattes.cnpq.br/8701042043901034
dc.contributor.author.fl_str_mv Fonseca, Marina Brand?o da
contributor_str_mv Graebin, Cedric Stephan
Andricopulo, Adriano Defini
Graebin, Cedric Stephan
K?mmerle, Arthur Engen
Limberger, Jones
dc.subject.por.fl_str_mv Rea??o multicomponente
c?ncer
Tubulina
topic Rea??o multicomponente
c?ncer
Tubulina
Multicomponent reaction
cancer
Qu?mica
dc.subject.eng.fl_str_mv Multicomponent reaction
cancer
dc.subject.cnpq.fl_str_mv Qu?mica
description Today, cancer is one of the most deadly diseases in the world. Breast cancer is the fifth most lethal, and its triple negative subtype has the highest mortality rate. There is no specific treatment for the triple negative subtype, and the high rates of disease recurrence and metastasis make it necessary to search for new forms of treatment. A multicomponent reaction is a type of reaction for chemical synthesis, where three or more reagents react to form a single product with a high degree of chemical diversity, and the Hantzsch reaction is one of the first reactions of this type reported. In the present work, a series of molecules were synthesized, using as a basis the Hantzsch reaction and structures analogous to natural products such as Colchicine and Podophyllotoxin, aiming at the optimization of the LDQMC-014 (7-(3,4,5-trimethoxyphenyl)-9,10,11,12-tetrahydrobenzo[c]acridin-8(7H)-one) prototype, whose results in previous works demonstrate good cytotoxic activity in vitro, with a profile of inhibition of Tubulin polymerization (target widely validated as anticancer). Varied yields were obtained with confirmation of the structures by carbon and hydrogen NMR. Once the LDQMC-014 compound obtained satisfactory results, it was sought to optimize the synthesis results. Systematic changes were made in the synthesis parameters, which promoted an increase of more than 78 % in the reaction yield. The enantiomers of LDQMC-014 were separated by chiral chromatography, which provided good enantiomeric separation, which subsequently allowed the determination of the absolute configuration of the asymmetric center present by circular dichroism. Once the enantiomers were isolated, their biological evaluations were performed in order to determine their activity, as well as a molecular modeling study to predict the interaction of the isolated enantiomers with the Tubulin protein. That enantiomers interact differently with the protein in both the in silico and the in vitro tests. The molecular modeling study was extended to all intended acridinones to predict a possible interaction with the Tubulin protein. A cell migration test (Wound Healing) was performed for some of the obtained acridinones, which determined the inhibition profile of cell migration, a desired characteristic in metastasis cases.
publishDate 2020
dc.date.issued.fl_str_mv 2020-01-28
dc.date.accessioned.fl_str_mv 2023-01-30T18:02:50Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/masterThesis
format masterThesis
status_str publishedVersion
dc.identifier.citation.fl_str_mv FONSECA, Marina Brand?o da. Otimiza??o do prot?tipo LDQMC-014: uma acridinona inibidora da polimeriza??o de Tubulina. 2020. 129 f. Disserta??o (Mestrado em Qu?mica) - Instituto de Qu?mica, Universidade Federal Rural do Rio de Janeiro, Serop?dica, RJ, 2020.
dc.identifier.uri.fl_str_mv https://tede.ufrrj.br/jspui/handle/jspui/6290
identifier_str_mv FONSECA, Marina Brand?o da. Otimiza??o do prot?tipo LDQMC-014: uma acridinona inibidora da polimeriza??o de Tubulina. 2020. 129 f. Disserta??o (Mestrado em Qu?mica) - Instituto de Qu?mica, Universidade Federal Rural do Rio de Janeiro, Serop?dica, RJ, 2020.
url https://tede.ufrrj.br/jspui/handle/jspui/6290
dc.language.iso.fl_str_mv por
language por
dc.relation.references.por.fl_str_mv ALBINI, A. et al. A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer research, v. 47, n. 12, p. 3239?45, jun 1987. ISSN 0008-5472. Citado na p?gina 73. ANVISA. Tecentriq?R (atezolizumabe): nova indica??o - Informa??es T?cnicas - Anvisa. 2019. Dispon?vel em: <http://portal.anvisa.gov.br/informacoes-tecnicas13?p{\_}p{\_}id=101{\_ }INSTANCE{\_}WvKKx2fhdjM2{&}p{\_}p{\_}col{\_}id=column-2{&}p{\_}p{\_}col{\_ }pos=1{&}p{\_}p{\_}col{\_}count=2{&}{\_}101{\_}INSTANCE{\_}WvKKx2fhdjM2{\_ }groupId=219201{&}{\_}101{\_}IN>. Citado na p?gina 3. ARNST, K. E. et al. Current advances of tubulin inhibitors as dual acting small molecules for cancer therapy. Medicinal Research Reviews, v. 39, n. 4, p. 1398?1426, 2019. ISSN 10981128. Citado na p?gina 5. BARREIRO, E. J. et al. Modelagem molecular: uma ferramenta para o planejamento racional de f?rmacos em qu?mica medicinal. [S.l.], 1997. v. 20, n. 1. Citado na p?gina 13. BARREIRO, E. J.; FRAGA, C. A. M. Qu?mica medicinal: as bases moleculares da a??o dos f?rmacos. 3a. ed. [S.l.]: Artmed, 2015. 608 p. ISBN 978-8582711170. Citado na p?gina 12. BIGGS-HOUCK, J. E.; YOUNAI, A.; SHAW, J. T. Recent advances in multicomponent reactions for diversity-oriented synthesis. Current Opinion in Chemical Biology, Elsevier Ltd, v. 14, n. 3, p. 371?382, 2010. ISSN 13675931. Citado na p?gina 7. CHUNG, T. W. et al. Multicomponent Synthesis of Functionalized Tetrahydroacridinones: Insights into a Mechanistic Route. Organic Letters, v. 17, n. 21, p. 5368?5371, 2015. ISSN 15237052. Citado 3 vezes nas p?ginas 8, 10 e 11. CLINICALTRIALS. Search of: AVE8062 - List Results - ClinicalTrials.gov. 2019. Dispon?vel em: <https://clinicaltrials.gov/ct2/results?cond={&}term=AVE8062{&}cntry={&}state={&}>. Citado na p?gina 6. CLINICALTRIALS. Search of: BNC-105p - List Results - ClinicalTrials.gov. 2019. Dispon?vel em: <https://clinicaltrials.gov/ct2/results?term=BNC-105p{&}age{\_}v={&}gndr={&}type= {&}rsl>. Citado na p?gina 6. CLINICALTRIALS. Search of: CA-1P - List Results - ClinicalTrials.gov. 2019. Dispon?vel em: <https://clinicaltrials.gov/ct2/results?cond={&}term=CA-1P{&}cntry={&}state={&}>. Citado na p?gina 6. CLINICALTRIALS. Search of: CA-4P - List Results - ClinicalTrials.gov. 2019. Dispon?vel em: <https://clinicaltrials.gov/ct2/results?cond={&}term=CA-4P{&}cntry={&}state={&}>. Citado na p?gina 6. CLINICALTRIALS. Search of: CKD-516 - List Results - ClinicalTrials.gov. 2019. Dispon?vel em: <https://clinicaltrials.gov/ct2/results?term=CKD-516{&}age{\_}v={&}gndr={&}type={&}rsl>. Citado na p?gina 6. CLINICALTRIALS. Search of: ZD6126 - List Results - ClinicalTrials.gov. 2019. Dispon?vel em: <https://clinicaltrials.gov/ct2/results?cond={&}term=ZD6126{&}cntry={&}state={&}>. Citado na p?gina 6. CRABB?, P. Actividad optica, dispersi?n rotatoria optica y dicroismo circular en qu?mica organica. [S.l.]: Programa Regional de Desarrollo Cient?fico y Tecnol?gico, 1974. 68 p. ISBN 082701418X 9780827014183. Citado na p?gina 45. DAWOOD, S. Triple-Negative Breast Cancer. Drugs, v. 70, n. 17, p. 2247?2258, dec 2010. ISSN 0012-6667. Citado na p?gina 2. DEANGELIS, G.; WILDMAN, W. Circular dichroism studies?I: A quadrant rule for the optically active aromatic chromophore in rigid polycyclic systems. Tetrahedron, v. 25, n. 20, p. 5099?5112, jan 1969. ISSN 00404020. Citado na p?gina 45. DUMONTET, C.; JORDAN, M. A. Microtubule-binding agents: a dynamic field of cancer therapeutics. Nature Reviews Drug Discovery, v. 9, n. 10, p. 790?803, oct 2010. ISSN 1474-1776. Citado na p?gina 5. EVDOKIMOV, N. M. et al. Structural Simplification of Bioactive Natural Products with Multicomponent Synthesis. 3. Fused Uracil-Containing Heterocycles as Novel Topoisomerase- Targeting Agents. Journal of Medicinal Chemistry, v. 54, n. 7, p. 2012?2021, apr 2011. ISSN 0022-2623. Citado na p?gina 51. FONSECA, M. B. S?ntese de heterociclos com atividade antic?ncer. 2017. Trabalho de conclus?o de curso (Gradua??o). UFRRJ, Serop?dica. Citado 6 vezes nas p?ginas 13, 14, 17, 30, 38 e 69. FOULKES, W. D.; SMITH, I. E.; REIS-FILHO, J. S. Triple-Negative Breast Cancer. New England Journal of Medicine, v. 363, n. 20, p. 1938?1948, nov 2010. ISSN 0028-4793. Citado 2 vezes nas p?ginas 2 e 3. GRAEBIN, C. S. et al. Multicomponent Reactions for the Synthesis of Bioactive Compounds: A Review. Current Organic Synthesis, v. 16, n. 6, p. 855?899, nov 2019. ISSN 15701794. Citado na p?gina 7. BROOKS, W. H.; GUIDA, W. C.; DANIEL, K. G. The Significance of Chirality in Drug Design and Development. Current Topics in Medicinal Chemistry, v. 11, n. 7, p. 760?770, apr 2011. ISSN 15680266. Citado na p?gina 12. HANTZSCH, A. Ueber die Synthese pyridinartiger Verbindungen aus Acetessig?ther und Aldehydammoniak. Justus Liebig?s Annalen der Chemie, v. 215, n. 1, p. 1?82, 1882. ISSN 00754617. Citado na p?gina 8. HSL. C?ncer de mama triplo-negativo - Hospital S?rio-Liban?s. 2019. Dispon?vel em: <https://www.hospitalsiriolibanes.org.br/sua-saude/Paginas/ cancer-mama-triplo-negativo-imunoterapia-tratamento.aspx>. Citado na p?gina 2. HYEDA, A.; SBARDELLOTTO, ?.; DA COSTA, M. Uma an?lise preliminar dos custos em quimioterapia ambulatorial no sistema de sa?de suplementar A preliminary analysis of the costs for outpatient chemotherapy in the supplementary health system. J Bras Econ Sa?de, v. 7, n. 2, p. 99?109, 2015. Citado na p?gina 1. IARC. Cancer Today. 2019. Dispon?vel em: <https://gco.iarc.fr/today/online-analysis-pie? v=2018{&}mode=cancer{&}mode{_}population=continents{&}population= 900{&}populations={&}key=total{&}sex=0{&}cancer=39{&}type=0{&}statistic= 5{&}prevalence=0{&}population{_}group=0{&}ages{_}group{%}>. Citado na p?gina 2. IARC. Cancer Today. 2019. Dispon?vel em: <https://gco.iarc.fr/today/online-analysis-pie? v=2018{&}mode=cancer{&}mode{\_}population=continents{&}population= 900{&}populations=76{&}key=total{&}sex=0{&}cancer=39{&}type=0{&}statistic= 5{&}prevalence=0{&}population{\_}group=0{&}ages{\_}group{}>. Citado na p?gina 2. IARC. Cancer Today. 2019. Dispon?vel em: <https://gco.iarc.fr/today/online-analysis-pie? v=2018{&}mode=cancer{&}mode{\_}population=continents{&}population= 900{&}populations=900{&}key=total{&}sex=0{&}cancer=39{&}type=1{&}statistic= 5{&}prevalence=0{&}population{\_}group=0{&}ages{\_}group>. Citado na p?gina 2. IARC. Cancer Today. 2019. Dispon?vel em: <https://gco.iarc.fr/today/online-analysis-pie? v=2018{&}mode=cancer{&}mode{\_}population=continents{&}population= 900{&}populations=900{&}key=total{&}sex=0{&}cancer=39{&}type=2{&}statistic= 5{&}prevalence=1{&}population{\_}group=0{&}ages{\_}group>. Citado na p?gina 2. IARC. Cancer Tomorrow. 2019. Dispon?vel em: <https://gco.iarc.fr/tomorrow/graphic-isotype? type=0{&}population=900{&}mode=population{&}sex=0{&}cancer=39{&}age{\_}group= value{&}ap>. Citado 2 vezes nas p?ginas 8 e 1. IARC. Cancer Tomorrow. 2019. Dispon?vel em: <https://gco.iarc.fr/tomorrow/graphic-isotype? type=0{&}population=900{&}mode=population{&}sex=2{&}cancer=39{&}age{\_}group= value{&}ap>. Citado 2 vezes nas p?ginas 8 e 2. INCA. Contra o triplo-negativio. Rede C?ncer 08, p. 44, 2009. Citado na p?gina 2. INCA. O que ? c?ncer? | INCA - Instituto Nacional de C?ncer. 2019. Dispon?vel em: <https://www.inca.gov.br/o-que-e-cancer>. Citado na p?gina 1. INCA. Quais os efeitos colaterais da quimioterapia? | INCA - Instituto Nacional de C?ncer. 2019. Dispon?vel em: <https://www.inca.gov.br/perguntas-frequentes/ quais-os-efeitos-colaterais-da-quimioterapia>. Citado na p?gina 1. INCA. Quimioterapia | INCA - Instituto Nacional de C?ncer. 2019. Dispon?vel em: <https://www.inca.gov.br/tratamento/quimioterapia>. Citado na p?gina 1. INCA. Tipos de c?ncer | INCA - Instituto Nacional de C?ncer. 2019. Dispon?vel em: <https://www.inca.gov.br/tipos-de-cancer/cancer-de-mama>. Citado na p?gina 2. INCA. Tratamento do c?ncer | INCA - Instituto Nacional de C?ncer. 2019. Dispon?vel em: <https://www.inca.gov.br/tratamento>. Citado na p?gina 1. KAVALLARIS, M. Microtubules and resistance to tubulin-binding agents. Nature Reviews Cancer, v. 10, n. 3, p. 194?204, mar 2010. ISSN 1474175X. Citado na p?gina 3. LI, L. et al. Recent advances in trimethoxyphenyl (TMP) based tubulin inhibitors targeting the colchicine binding site. European Journal of Medicinal Chemistry, Elsevier Masson SAS, v. 151, p. 482?494, 2018. ISSN 17683254. Citado na p?gina 5. LIANG, C. C.; PARK, A. Y.; GUAN, J. L. In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nature Protocols, v. 2, n. 2, p. 329?333, feb 2007. ISSN 1754-2189. Citado na p?gina 73. LIMA, V. L. E. Os f?rmacos e a quiralidade: uma breve abordagem. [S.l.], 1997. v. 20, n. 6. Citado na p?gina 12. MAGALHAES, L. G. Planejamento e caracteriza??o de moduladores da prote?na tubulina candidatos a f?rmacos para o tratamento de c?ncer. 2019. Tese (Doutorado). USP, S?o Carlos. Citado 8 vezes nas p?ginas 9, 3, 13, 19, 20, 55, 56 e 69. MAGALHAES, L. G. et al. Discovery of a series of acridinones as mechanism-based tubulin assembly inhibitors with anticancer activity. PLoS ONE, v. 11, n. 8, p. 1?17, 2016. ISSN 19326203. Citado 3 vezes nas p?ginas 14, 55 e 69. MAKRIYANNIS, A.; BIEGEL, D. Drug Discovery Strategies and Methods. [S.l.]: CRC Press, 2003. 338 p. ISBN 9780203913277. Citado na p?gina 3. MUSTACCHI, G.; DE LAURENTIIS, M. The role of taxanes in triple-negative breast cancer: literature review. Drug Design, Development and Therapy, p. 4303, aug 2015. ISSN 1177-8881. Citado na p?gina 2. NOBREGA, C. R.; LIMA, A. F. C. Procedures? costs related to outpatient chemotherapy treatment of women suffering from breast cancer. Revista da Escola de Enfermagem da USP, v. 48, n. 4, p. 699?705, aug 2014. ISSN 0080-6234. Citado na p?gina 1. PEREZ, E. A. Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance. Molecular Cancer Therapeutics, v. 8, n. 8, p. 2086?2095, aug 2009. ISSN 15357163. Citado na p?gina 3. PETTIT, G. R. et al. Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4. Experientia, v. 45, n. 2, p. 209?211, feb 1989. ISSN 0014-4754. Citado na p?gina 19. PROTEOMICSCREATIVE. Molecular Docking Service. 2019. Dispon?vel em: <https: //www.creative-proteomics.com/services/molecular-docking-service.htm>. Citado 2 vezes nas p?ginas 8 e 13. ROGERIO, K. R. et al. Multicomponent reactions: A brief history and their versatility for the synthesis of biologically active molecules. Revista Virtual de Quimica, v. 8, n. 6, p. 1934?1962, 2016. ISSN 19846835. Citado 2 vezes nas p?ginas 8 e 7. ROSADO, J. O. An?lise de redes de intera??es entre drogas quimioter?picas usadas no tratamento de c?ncer g?strico: explorando prote?nas e processos biol?gicos por meio de ferramentas de farmacologia de sistemas. 2010. Disserta??o (mestrado). UFRGS, Porto Alegre. Citado na p?gina 13. SAINI, A.; KUMAR, S.; SANDHU, J. S. Hantzsch reaction: Recent advances in Hantzsch 1,4-dihydropyridines. Journal of Scientific and Industrial Research, v. 67, n. 2, p. 95?111, 2008. ISSN 00224456. Citado na p?gina 9. SALUM, L. B. Planejamento de ligantes da tubulina com propriedades antitumorais. 2011. Tese (Doutorado). USP, S?o Carlos. Citado na p?gina 3. SCHMID, P. et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. New England Journal of Medicine, v. 379, n. 22, p. 2108?2121, nov 2018. ISSN 0028-4793. Citado na p?gina 3. SOLOMONS, T. W. G.; FRYHLE, C. B. Qu?mica Org?nica. 10. ed. [S.l.: s.n.], 2012. ISBN 9788521620334. Citado na p?gina 11. SOUZA, S. Estudo de inibidores de colinesterases aplicando t?cnicas de QSAR-2D (HQSAR) e docking molecular. 2012. Tese (Doutorado). UFRJ, Rio de Janeiro. Citado na p?gina 13. STEINMETZ, M. O.; PROTA, A. E. Microtubule-Targeting Agents: Strategies To Hijack the Cytoskeleton. Trends in Cell Biology, Elsevier Ltd, v. 28, n. 10, p. 776?792, 2018. ISSN 18793088. Citado 3 vezes nas p?ginas 8, 4 e 7. TRATRAT, C.; GIORGI-RENAULT, S.; HUSSON, H. A Multicomponent Reaction for the One-Pot Synthesis of 4-Aza-2,3-didehydropodophyllotoxin and Derivatives. Organic Letters, v. 4, n. 19, p. 3187?3189, sep 2002. ISSN 1523-7060. Citado 6 vezes nas p?ginas 8, 9, 10, 26, 39 e 63. WADE, R. H. On and Around Microtubules: An Overview. Molecular Biotechnology, v. 43, n. 2, p. 177?191, oct 2009. ISSN 1073-6085. Citado na p?gina 3. WERMUTH, C. G. The practice of Medicinal Chemistry. 3a. ed. [S.l.]: Academic Press, 2008. ISBN 9780123741943. Citado na p?gina 55.
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Universidade Federal Rural do Rio de Janeiro
dc.publisher.program.fl_str_mv Programa de P?s-Gradua??o em Qu?mica
dc.publisher.initials.fl_str_mv UFRRJ
dc.publisher.country.fl_str_mv Brasil
dc.publisher.department.fl_str_mv Instituto de Qu?mica
publisher.none.fl_str_mv Universidade Federal Rural do Rio de Janeiro
dc.source.none.fl_str_mv reponame:Biblioteca Digital de Teses e Dissertações da UFRRJ
instname:Universidade Federal Rural do Rio de Janeiro (UFRRJ)
instacron:UFRRJ
instname_str Universidade Federal Rural do Rio de Janeiro (UFRRJ)
instacron_str UFRRJ
institution UFRRJ
reponame_str Biblioteca Digital de Teses e Dissertações da UFRRJ
collection Biblioteca Digital de Teses e Dissertações da UFRRJ
bitstream.url.fl_str_mv http://localhost:8080/tede/bitstream/jspui/6290/4/2020+-+Marina+Brand%C3%A3o+da+Fonseca.pdf.jpg
http://localhost:8080/tede/bitstream/jspui/6290/3/2020+-+Marina+Brand%C3%A3o+da+Fonseca.pdf.txt
http://localhost:8080/tede/bitstream/jspui/6290/2/2020+-+Marina+Brand%C3%A3o+da+Fonseca.pdf
http://localhost:8080/tede/bitstream/jspui/6290/1/license.txt
bitstream.checksum.fl_str_mv ab8f7143f6da57e76b9d97505ead73f3
2960e5091fa598b0d3b3ff01a24bd01b
f402c8b500ccf14a6fee41d64330174a
7b5ba3d2445355f386edab96125d42b7
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
MD5
repository.name.fl_str_mv Biblioteca Digital de Teses e Dissertações da UFRRJ - Universidade Federal Rural do Rio de Janeiro (UFRRJ)
repository.mail.fl_str_mv bibliot@ufrrj.br||bibliot@ufrrj.br
_version_ 1800313563894513664